CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2009; 30(S 01): 33-34
DOI: 10.1055/s-0041-1733339
Original Article

Management : Adnexal mass in pregnant women

Rama Joshi
Department of Gynacologic Oncology, Dharmshila Cancer Hospital, New Delhi, India
› Author Affiliations

Publication History

Article published online:
02 March 2022

© 2009. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Bernhard LM, Klebba PK, Gray DL, Mutch DG. Predictors of persistence of adnexal masses in pregnancy. Obstet Gynecol. 1999; 93: 585 –589.
  • 2 Platek DN, Henderson CE, Goldberg GL. The management of a persistent adnexal mass in pregnancy. Am J Obstet Gynecol. 1995; 173: 1236 –1240.
  • 3 Bromley B, Benacerraf B. Adnexal masses duringpregnancy: accuracy of sonographic diagnosis and outcome. J Ultrasound Med. 1997; 16: 447 –452.
  • 4 Roberts JA. Management of gynaecologic tumours during pregnancy. Clin Perinatol 1983;10:369-382.
  • 5 Sherard GB 3rd, Hodson CA, Williams HJ , et al. Ad.nexal masses and pregnancy: a 12 year experience. Am J Obstet Gynecol. 2003; 189: 358 –363.
  • 6 Bromley B, Benacerraf B. Adnexal masses during pregnancy: accuracy of sonographic diagnosis and outcome. J Ultrasound Med. 1997; 16: 447 –452.
  • 7 Kobayashi F,Sagawa N, Nakamura K et al. Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women.Am J Obstet Gynecol 1989;160:563-566
  • 8 Whitecar P, Turner S, Higby K. Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management. Am J Obstet Gynecol. 1999; 181: 19 –24.
  • 9 Novak ER,Lambrou CD,Woodruff JD.Ovarian tumours in pregnancy, An ovarian tumour registry review. Obstet Gynecol 1975;46:401-406.
  • 10 Leiserowitz GS, Xing G, Cress R, Brahmbhatt B, Dalrymple JL, Smith LH. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol. 2006;101:315–321.
  • 11 Reedy MB, Källén B, Kuehl TJ. Laparoscopy during pregnancy: a study of five fetal outcome parameters with use of the Swedish health registry. Am J Obstet Gynecol. 1997; 177: 673 –679.
  • 12 Schilder JM, Thompson AM, DePriest PD , et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002; 87: 1 –7.
  • 13 Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumours of the ovary. Obstet Gynecol. 2003; 101: 251 –257.
  • 14 Christman JE, Teng NN,Lebovic GS,Sikic BI Delivery of normal infant following Cisplatin ,Vinblastin,and Bleomycin(PVB) Chemotherapy for malignant teratoma of the ovary during pregnancy.Gynecol Oncol 1990;37:292-295.
  • 15 King LA, Nevin PC, William pp, Carson LF.Treatment of advanced epithelial ovarian carcinoma in pregnancywith Cisplatin-based chemotherapy.Gynecol Oncol 1991;41:78-80.
  • 16 Ferrandina G, Distefano M, Testa A, De Vincenzo R, Scambia G. Management of an advanced ovarian cancer at 15 weeks of gestation: case report and literature review. Gynecol Oncol. 2005; 97: 693 –696.